SMTI (Sanara MedTech) Forward Dividend Yield %: 0.00% (As of Jun. 27, 2026)


SMTI Sanara MedTech Inc SMTI
72 GF Score
Price $23.88
GF Value $45.54
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Sanara MedTech Forward Dividend Yield %?

Sanara MedTech SMTI +2.98% 72 Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.54 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 316 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 316455.38% on this metric.

As of today (2026-06-27), the Forward Annual Dividend Yield of Sanara MedTech is 0.00%.

As of today (2026-06-27), the Trailing Annual Dividend Yield of Sanara MedTech is 0.00%.

SMTI's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.09
* Ranked among companies with meaningful Forward Dividend Yield % only.

Sanara MedTech's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Sanara MedTech  (NAS:SMTI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Sanara MedTech Forward Dividend Yield % Related Terms


SMTI vs PDEX, UTMD, EMBC: Forward Dividend Yield % Comparison

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech Forward Dividend Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Forward Dividend Yield % falls into.


SMTI
72GF Score
Sanara MedTech Inc SMTI
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanara MedTech Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Sanara MedTech (SMTI) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #999999 out of 316 companies in the Medical Devices & Instruments industry.
Is Sanara MedTech's Forward Dividend Yield % too high?
Sanara MedTech's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Sanara MedTech ranks #999999 out of 316 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Forward Dividend Yield % compare to PDEX and UTMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #999999 out of 316 companies for Forward Dividend Yield %. This places Sanara MedTech in the lower half of its industry. The industry median Forward Dividend Yield % is 2.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.09, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.54, compared to a current price of $23.88 — trading 47.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $23.88 is trading 47.6% below its estimated GF Value™ of $45.54. GuruFocus considers Sanara MedTech to be Possible Value Trap.

Key valuation signals for SMTI:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: $45.54 vs. price of $23.88 (47.6% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score

Get the complete analysis for SMTI

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.88
Price
$45.54
GF Value